| Name | CeMMEC1 |
| Description | CeMMEC1 is an inhibitor of BRD4, and also has a great affinity for TAF1(IC50=0.9 μM). |
| Cell Research | REDS3 cells were treated with CeMMEC1(10 μM) incubating for 24 hours. |
| Kinase Assay | TAF1 binding assays are conducted using the EPIgeneous Binding Domain kit B. Binding is determined by the displacement of an acetylated biotin peptide from a GST-tagged TAF1 protein using HTRF with a Eu3+-conjugated GST antibody donor and streptavidin-conjugated acceptor. Compounds (CeMMEC1) are dispensed into assay plates, ProxiPlate-384 Plus using an Echo 525 Liquid Handler. Binding assays are conducted in a final volume of 20 μL with 5 nM TAF1-GST, 50 nM peptide (SGRGK (ac)GGK (ac)GLGK (ac)GGAK (ac)RHRK (biotin)-acid), 6.25 nM Streptavidin-XL665, 1:200 Anti-GST-Eu3+ cryptate and 0.1% DMSO. Assay reagents are dispensed into plates using a Multidrop combi and incubated at room temperature for 3 h. Fluorescence is measured using a PHERAstar microplate reader using the HTRF module with dual emission protocol (A = excitation of 320 nm, emmission of 665 nm, and B = excitation of 320 nm, emission of 620 nm). Raw data are processed to give an HTRF ratio (channel A/B × 10,000), which is used to generate IC50 curves |
| In vitro | CeMMEC1 exhibits high affinity activity for the bromodomains of CREBBP, EP300, BRD9 and the second bromodomain of TAF1. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 5.63 mg/mL (16.74 mM), Sonication is recommended.
|
| Keywords | TAF1 | RNASynthesis | RNA Synthesis | EpigeneticReaderDomain | Epigenetic Reader Domain | DNASynthesis | DNA/RNA Synthesis | DNA Synthesis | CeMMEC-1 | CeMMEC1 | CeMMEC 1 | BRD4 |
| Inhibitors Related | 5-Fluorouracil | Procaine | Rifaximin | Ribavirin | Guanidine hydrochloride | Curcumin | N-Nitrosodiethylamine | Cytarabine | Thymidine | Naphthol AS-E | Temozolomide | Folic acid |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Epigenetics Compound Library | Kinase Inhibitor Library | Chromatin Modification Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Metabolism Disease Compound Library |
United States
